Recorlev Leads to Sustained Improvements in Cortisol Control in Cushing’s Syndrome, Phase 3 Trial Shows
The oral investigational treatment Recorlev (levoketoconazole) leads to sustained improvements in the control of cortisol among patients with endogenous Cushing’s syndrome, a Phase 3 trial shows. The trial’s findings were reported in the study “Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing’s…